Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity

BACKGROUND: With the development of targeted agents, the approach to combination cancer therapy has evolved to focus on identifying ways in which pathway inhibition by one agent may enhance the activity of other agents. In theory, this implies that under this new paradigm, agents are no longer requi...

Descripción completa

Detalles Bibliográficos
Autores principales: Foster, Jared, Freidlin, Boris, Korn, E L, Smith, Malcolm
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597487/
https://www.ncbi.nlm.nih.gov/pubmed/33122353
http://dx.doi.org/10.1136/esmoopen-2020-000871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7597487/
https://www.ncbi.nlm.nih.gov/pubmed/33122353
http://dx.doi.org/10.1136/esmoopen-2020-000871

Ejemplares similares